Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a minor version update to the page. No substantive study content changes are introduced.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing v3.6.0. This indicates a minor platform update and does not alter study details or participant information.SummaryDifference0.0%

- Check36 days agoChange DetectedThe page adds a recruitment status update indicating no longer looking for participants, clarifying that enrollment is closed. It also adds user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and includes a small formatting adjustment to the Intervention/Treatment header along with a new site revision version (v3.6.0).SummaryDifference0.3%

- Check43 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new release of the page template or minor maintenance. This change does not alter study data or user-visible content.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page's Revision value was updated from v3.5.3 to v3.5.4, indicating a minor update to the record's metadata or formatting rather than substantive content changes.SummaryDifference0.0%

- Check86 days agoChange DetectedThe page’s footer revision/version was updated from v3.5.2 to v3.5.3, indicating a site build change without altering the displayed clinical trial study information.SummaryDifference0.0%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.